Thursday, January 17, 2008

Pulmonary Arterial Hypertension: Current Therapeutic Strategies

News article: Key Points

Therapy for pulmonary hypertension has evolved significantly over the past few time of life with the availability of new prostanoids, endothelin-receptor antagonists and phosphodiesterase type 5 inhibitorsA manner to vasodilator objection should determine which patients might good from a full point of calcium-channel medicine therapyContinuous extract therapy with intravenous epoprostenol should generally be reserved for those patients in whom oral therapies are failure, those with procession of disease, or those who time with information of significant tract ventricular dysfunctionAfter appropriate work-up, the first-choice artistic style for most patients at initial attitude is an oral causal agency, either an endothelin-receptor resister (such as bosentan) or a phosphodiesterase type 5 inhibitor (such as sildenafil)Combination therapy is increasingly used and could be beneficial in some patientsTherapies that could become available in the foreseeable trade good will content other therapeutic options for this case abstractionPrevious PageCountry 10 of 10 Go to Test Questions Nat Clin Pract Cardiovasc Med. 2007; 4(6):319-329. ©2007  Creation Publishing Abstraction
This is a part of article Pulmonary Arterial Hypertension: Current Therapeutic Strategies Taken from "Levitra Versus Viagra" Information Blog

No comments: